Drug Trial Radar · NCT06961214
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
961
Planned (sponsor's estimate)
Start
Jun 23, 2025
Primary completion
Dec 13, 2028
Study completion Feb 14, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
DepemokimabBiological
Depemokimab as a sterile liquid formulation will be administered.
PlaceboDrug
Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Moderate/Severe ExacerbationsTime frame: From Baseline up to Week 104
Locations
193 sites in 16 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Sheffield, Alabama · Recruiting
GSK Investigational Site
Aurora, Colorado · Recruiting
GSK Investigational Site
Brooksville, Florida · Recruiting
GSK Investigational Site
Doral, Florida · Recruiting
GSK Investigational Site
Fort Lauderdale, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami Lakes, Florida · Recruiting
GSK Investigational Site
Naples, Florida · Recruiting
GSK Investigational Site
New Port Richey, Florida · Recruiting
GSK Investigational Site
Ocala, Florida · Recruiting
GSK Investigational Site
Orlando, Florida · Recruiting
GSK Investigational Site
Ormond Beach, Florida · Recruiting
GSK Investigational Site
Palmetto Bay, Florida · Recruiting
GSK Investigational Site
Pembroke Pines, Florida · Recruiting
GSK Investigational Site
St. Petersburg, Florida · Recruiting
GSK Investigational Site
Adairsville, Georgia · Recruiting
GSK Investigational Site
Atlanta, Georgia · Recruiting
GSK Investigational Site
Cordele, Georgia · Recruiting
GSK Investigational Site
Morrow, Georgia · Recruiting
GSK Investigational Site
Boise, Idaho · Recruiting
GSK Investigational Site
Chicago, Illinois · Recruiting
GSK Investigational Site
Baton Rouge, Louisiana · Recruiting
GSK Investigational Site
Lafayette, Louisiana · Recruiting
GSK Investigational Site
Shreveport, Louisiana · Recruiting
GSK Investigational Site
Bangor, Maine · Recruiting
GSK Investigational Site
Rockville, Maryland · Recruiting
GSK Investigational Site
Fall River, Massachusetts · Recruiting
GSK Investigational Site
Allen Park, Michigan · Recruiting
GSK Investigational Site
Detroit, Michigan · Recruiting
GSK Investigational Site
Garden City, Michigan · Recruiting
GSK Investigational Site
Troy, Michigan · Recruiting
GSK Investigational Site
Las Vegas, Nevada · Recruiting
GSK Investigational Site
Moorestown, New Jersey · Recruiting
GSK Investigational Site
Sewell, New Jersey · Recruiting
Showing 40 of 193 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.